Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Labetuzumab govitecan|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Labetuzumab govitecan||IMMU-130||Labetuzumab govitecan (IMMU-130) is an antibody-drug conjugate comprised of CEACAM5 monoclonal antibody linked to the active metabolite of irinotecan (SN-38), which has potential antitumor activity (Journal of Clinical Oncology 2015 33:3_suppl, 625-625, PMID: 28817371, PMID: 30822636).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||colorectal cancer||not applicable||Labetuzumab govitecan||Phase Ib/II||Actionable||In a Phase I/II trial, treatment with Labetuzumab govitecan demonstrated safety and resulted in stable disease in 49% (42/86), a clinical benefit rate of 29% (25/86; 1 partial response and stable disease for at least 6 months in 24), a median progression-free survival of 3.6 months, and a median overall survival of 6.9 months in patients with previously treated recurrent or refractory colorectal cancer (PMID: 28817371; NCT01605318).||detail... 28817371|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|